drugset
drugset / Trial / NCT04741997

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

NCT04741997 ↗

Phase 0 Recruiting 50 enrolled H. Lee Moffitt Cancer Center and Research Institute Pfizer · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.

Timeline

Start
2021-05-24
Primary completion
2026-07-22
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Binimetinib Small molecule 45 mg Oral
Subject Encorafenib Small molecule 450 mg Oral
Subject Nivolumab Monoclonal antibody 480 mg Intravenous

Indications

metastatic melanoma